CU23837B1 - Quelatos metálicos con radical peg perfluorado - Google Patents

Quelatos metálicos con radical peg perfluorado

Info

Publication number
CU23837B1
CU23837B1 CU2009000059A CU20090059A CU23837B1 CU 23837 B1 CU23837 B1 CU 23837B1 CU 2009000059 A CU2009000059 A CU 2009000059A CU 20090059 A CU20090059 A CU 20090059A CU 23837 B1 CU23837 B1 CU 23837B1
Authority
CU
Cuba
Prior art keywords
metal chelates
perfluorated
radical
formula
peg
Prior art date
Application number
CU2009000059A
Other languages
English (en)
Other versions
CU20090059A7 (es
Inventor
Heiko Schirmer
Hanns-Joachim Weinmann
Johannes Platzek
Ludwig Zorn
Bernd Misselwitz
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20090059A7 publication Critical patent/CU20090059A7/es
Publication of CU23837B1 publication Critical patent/CU23837B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se revelan quelatos con radical PEG perfluorado de fórmula I ESPACIO PARA LA FÓRMULA en especial aquellos ejemplificados y reivindicados,útiles para el diagnóstico NMR y por rayos-X, radiodiagnóstico y radioterapia y para linfografía MRT. Los quelatos metálicos con radical PEG encuentran aplicación en la tomografía por resonancia magnética nuclear (MRT) para la visualización de diferentes estructuras fisiológicas y con ello, para mejorar informaciones diagnósticas, específicamente la localización y el grado de la enfermedad, la selección y el control del éxito de una terapia puntual y para la profilaxis.
CU2009000059A 2006-10-18 2009-04-17 Quelatos metálicos con radical peg perfluorado CU23837B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006049821A DE102006049821A1 (de) 2006-10-18 2006-10-18 Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US85296306P 2006-10-20 2006-10-20
US89007107P 2007-02-15 2007-02-15
PCT/EP2007/007284 WO2008046463A1 (de) 2006-10-18 2007-08-11 Metallchelate mit perfluoriertem peg-rest, verfahren zu deren herstellung sowie deren verwendung

Publications (2)

Publication Number Publication Date
CU20090059A7 CU20090059A7 (es) 2011-03-21
CU23837B1 true CU23837B1 (es) 2012-10-15

Family

ID=38670854

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000059A CU23837B1 (es) 2006-10-18 2009-04-17 Quelatos metálicos con radical peg perfluorado

Country Status (21)

Country Link
US (1) US8263040B2 (es)
EP (1) EP2089362A1 (es)
JP (1) JP5475454B2 (es)
KR (1) KR101451446B1 (es)
CN (1) CN101687803B (es)
AU (1) AU2007312691A1 (es)
BR (1) BRPI0717466A2 (es)
CA (1) CA2666910C (es)
CO (1) CO6170342A2 (es)
CR (1) CR10727A (es)
CU (1) CU23837B1 (es)
DE (1) DE102006049821A1 (es)
GT (1) GT200900087A (es)
IL (1) IL198173A0 (es)
MX (1) MX2009004097A (es)
MY (1) MY148553A (es)
NO (1) NO20091912L (es)
NZ (1) NZ576249A (es)
RU (1) RU2470014C2 (es)
SG (1) SG177994A1 (es)
WO (1) WO2008046463A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021948A1 (en) * 2007-08-13 2009-02-19 Ge Healthcare As Chelators, paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (mri)
US11529309B2 (en) * 2016-04-29 2022-12-20 University Of Houston System Compositions, methods and kits for treating a contact lens
CN111138652B (zh) * 2018-05-16 2022-11-04 广州优尔材料科技有限公司 含全氟聚醚基的硅烷化合物、其制备方法、表面处理剂及物品
WO2020203671A1 (ja) * 2019-03-29 2020-10-08 ダイキン工業株式会社 フルオロポリエーテル基含有化合物
WO2025058000A1 (ja) 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び／又は診断用医薬組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588279A (en) * 1982-10-27 1986-05-13 Konishiroku Photo Industry Co., Ltd. Cleaning roller intermediate transfer member
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
EP0292306A3 (en) 1987-05-20 1989-09-13 Nippon Shokubai Co., Ltd. Methylolaminotriazine condensates and method for production thereof
US4838274A (en) 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE4008179A1 (de) * 1990-03-12 1991-09-19 Schering Ag Fluorbenzolsulfonamide
US5250283A (en) 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
US5318770A (en) 1991-10-25 1994-06-07 Mallinckrodt Medical, Inc. Trifluoromethyl analogs of X-ray contrast media for magnetic resonance imaging
DE4203254C2 (de) 1992-02-05 1996-05-02 Max Planck Gesellschaft Fluorhaltige Markierungsverbindung für NMR-Untersuchungen und deren Verwendung
US5482650A (en) * 1992-04-28 1996-01-09 Minnesota Mining And Manufacturing Company Liquid crystal compounds having perfluoroether terminal portions
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5401493A (en) 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
DE4317588C2 (de) * 1993-05-24 1998-04-16 Schering Ag Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung
JPH0797340A (ja) 1993-06-03 1995-04-11 Terumo Corp Ｍｒｉ造影剤組成物
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5702637A (en) * 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19744003B4 (de) 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
DE19744004C1 (de) 1997-09-26 1999-07-22 Schering Ag Lipophile Metall-Komplexe für Nekrose und Infarkt-Imaging
US6495118B1 (en) * 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
WO1999017809A2 (en) 1997-10-02 1999-04-15 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
DE19914101C1 (de) 1999-03-22 2000-10-12 Schering Ag Perfluoralkylamide, ihre Herstellung und ihre Verwendung in der Diagnostik
US6461587B1 (en) * 1999-03-22 2002-10-08 Schering Aktiengesellschaft Perfluoroalkylamides, their production and their use in diagnosis
DE19948651B4 (de) * 1999-09-29 2006-10-05 Schering Ag Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
US6939329B1 (en) * 1999-10-08 2005-09-06 Harvest Technologies Corporation Apparatus for holding and operating one or more syringes
DE10066210B4 (de) * 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
DE10040858C2 (de) 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
DE10040381C1 (de) * 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
US6641797B2 (en) * 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
RU2206605C1 (ru) * 2002-03-18 2003-06-20 Здоров Юрий Павлович Противоизносная присадка к смазочным средам и топливу
JP2005531647A (ja) * 2002-04-11 2005-10-20 カルボマー インク 新規なイメージングプローブ
US7344704B2 (en) * 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
JP2004101881A (ja) * 2002-09-10 2004-04-02 Konica Minolta Holdings Inc ドライイメージング材料
WO2005072780A2 (en) * 2004-01-16 2005-08-11 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
RU2296756C2 (ru) * 2005-05-17 2007-04-10 Федеральное унитарное государственное предприятие "Государственный научно-исследовательский институт биологического приборостроения" (ГосНИИ БП) Комплексообразующие дибензосодержащие пятичленные циклические соединения, содержащие два симметричных бета-дикарбонильных заместителя с фторированными радикалами

Also Published As

Publication number Publication date
MX2009004097A (es) 2009-07-10
CN101687803A (zh) 2010-03-31
SG177994A1 (en) 2012-02-28
NZ576249A (en) 2012-03-30
NO20091912L (no) 2009-07-17
CO6170342A2 (es) 2010-06-18
GT200900087A (es) 2010-04-19
MY148553A (en) 2013-04-30
CR10727A (es) 2009-07-23
IL198173A0 (en) 2009-12-24
HK1141526A1 (en) 2010-11-12
US8263040B2 (en) 2012-09-11
BRPI0717466A2 (pt) 2014-04-15
RU2009118486A (ru) 2010-11-27
AU2007312691A1 (en) 2008-04-24
CN101687803B (zh) 2012-05-30
KR20090082222A (ko) 2009-07-29
JP2010506862A (ja) 2010-03-04
CU20090059A7 (es) 2011-03-21
CA2666910C (en) 2013-12-24
US20080159954A1 (en) 2008-07-03
WO2008046463A1 (de) 2008-04-24
EP2089362A1 (de) 2009-08-19
KR101451446B1 (ko) 2014-10-16
JP5475454B2 (ja) 2014-04-16
CA2666910A1 (en) 2008-04-24
RU2470014C2 (ru) 2012-12-20
DE102006049821A1 (de) 2008-04-24

Similar Documents

Publication Publication Date Title
Izadifar et al. Mechanical and biological effects of ultrasound: a review of present knowledge
CU23837B1 (es) Quelatos metálicos con radical peg perfluorado
JOP20230216A1 (ar) عامل تباين جديد للاستخدام في التصوير بالرنين المغناطيسي
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
Ali et al. MRI in necrotizing fasciitis of the extremities
ES2545959T3 (es) Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer
NZ710436A (en) Biospecific agents for bone
UY29644A1 (es) Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes
WO2010039609A3 (en) Conjugates of hexose and metal coordinating compounds for imaging purposes
CL2025000135A1 (es) Compuesto agente de imagenología de diagnóstico tumoral específico de fap-alfa.
Nguyen et al. Cardiac MRI: a translational imaging tool for characterizing anthracycline-induced myocardial remodeling
ECSP088100A (es) Complejos con contenido de perfluoroalquilo, procedimientos para su preparación, así como su uso
Munhoz et al. Diffusion-weighted magnetic resonance imaging in maxillary sinuses inflammatory diseases: report of three cases and literature review
TW200717360A (en) Quantifiable symmetry criterion method
Testempassi et al. Constrictive tuberculous pericarditis diagnosed using 18F-fluorodeoxyglucose positron emission tomography: a report of two cases
De Filippo et al. Benefits of 3D technique in guiding percutaneous retroperitoneal biopsies
RU2014125849A (ru) Контрастное вещество для визуализации перфузии миокарда
ITMO20100025U1 (it) Dispositivo medico per l'utilizzo di uno strumento endoscopico a scopo diagnostico o operativo, particolarmente in urologia e ginecologia
Tamdy et al. Multiple mycotic aneurysms reveal Staphylococcus lugdunensis endocarditis in a young patient
AR120033A1 (es) Antagonista radiomarcado de grpr para uso como agente teragnóstico
CN201602897U (zh) 磁共振专用注射消毒盒
Lee et al. Intracranial gossypiboma mimicking a recurrent low grade astrocytoma: case report
Chung et al. Usefulness of plain radiographs for management of suspected fishbone impaction in digestive tract of children
AR053679A1 (es) Medios de contraste para la tomografia de resonancia magnetica nuclear utilizando el efecto overhauser
Ramam Linear epidermolytic acanthoma or adult-onset verrucous epidermal nevus?

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)